Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.
CONCLUSIONS: OMB/PTV/r+DSV±RBV is a cost-effective oral treatment regimen for chronic genotype 1 HCV infection compared with standard treatment regimens and is estimated to reduce the lifetime risks of advanced liver disease.
PMID: 27172133 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 17, 2016 Category: Health Management Tags: J Med Econ Source Type: research
Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C.
Authors: Kohjima M, Kurokawa M, Enjoji M, Yoshimoto T, Nakamura T, Ohashi T, Fukuizumi K, Harada N, Murata Y, Matsunaga K, Kato M, Kotoh K, Nakamuta M
Abstract
Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were ...
Source: Experimental and Therapeutic Medicine - May 16, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research
[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
CONCLUSIONS: Telaprevir-related dermatitis has a high incidence but is mostly of mild intensity. In most cases, tri-therapy was continued under close dermatological follow-up allowing rapid detection of rare instances of severe drug eruptions. Ribavirin and Interferon were thus continued even in the event of diffuse eruptions, enabling confirmation of the causative role of telaprevir in these eruptions.
PMID: 27161648 [PubMed - as supplied by publisher] (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - May 5, 2016 Category: Dermatology Authors: Lorcy S, Gaudy-Marqueste C, Botta D, Portal I, Quiles N, Oulies V, Mancini J, Grob JJ, Richard MA Tags: Ann Dermatol Venereol Source Type: research
The cost effectiveness of novel hepatits c therapies: a review
In the United States over 3 million individuals are infected with the Hepatitis C Virus (HCV) and 75% to 85% of them have or will develop Chronic Hepatitis C (CHC) which can lead to serious consequences such as liver cirrhosis, cancer, and death. Prior to 2013 the treatment of CHC was Pegylated Interferon + Ribavirin with or without a protease inhibitor such a Boceprevir/Telaprevir. These treatments had a cure rate or rate of sustained virologic response (SVR) of 66% to 80%. Since the close of 2013 several new direct acting agents (DAAs) for the treatment of CHC have been approved by the FDA. (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: C. Bickerstaff Source Type: research
Cost effectiveness of three antiviral treatments for hepatitis c virus chronic infection in peru
To compare the cost-effectiveness of dual treatment (pegylated interferon α and ribavirin [PEG-INF/RBV]) for Hepatitis C virus chronic infection against two triple treatments with boceprevir (PEG-INF/RBV/BOC) and telaprevir (PEG-INF/RBV/TVR). (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: R. Bolaños-Díaz, R.A. Tejada, C. Sanabria Source Type: research
Telaprevir-Induced Renal Adverse Events in Japanese Patients Reported in the PMDA Adverse Drug Reactions Reporting Database
Conclusions:
The number of reports of renal adverse events were highest in male patients 60 to 69 years of age treated with telaprevir. In addition, our findings suggested that anorexia is correlated with renal adverse events after telaprevir treatment. Further investigation is required to clarify the mechanism of renal impairments during triple therapy. Such knowledge might improve the safety of telaprevir therapy. (Source: Therapeutic Innovation and Regulatory Science)
Source: Therapeutic Innovation and Regulatory Science - April 20, 2016 Category: Drugs & Pharmacology Authors: Ichida, A., Motohashi, H., Kitano, A., Takayama, A., Inui, K.-i., Yano, Y. Tags: Global Perspectives Source Type: research
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
Conclusions. SVR12 was suitable for predicting persistent virologic response in almost all cases. In simeprevir-including regimens, SVR12 could not always predict persistent virologic response. Clinicians should use SVR24 for predicting treatment outcome in the use of HCV NS3/4A protease inhibitors with peginterferon plus ribavirin for any group of real-world patients chronically infected with HCV.
PMID: 27076789 [PubMed - in process] (Source: International Journal of Medical Sciences)
Source: International Journal of Medical Sciences - April 15, 2016 Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Barrier-independent, fitness-associated differences in sofosbuvir-efficacy against hepatitis C virus.
Abstract
Sofosbuvir displays a high phenotypic barrier to resistance, and it is a component of several combination therapies for hepatitis C virus (HCV) infections. HCV fitness can be a determinant of decreased sensitivity to direct acting antiviral agents such as telaprevir or daclatasvir, but fitness-dependent decreased drug sensitivity has not been established for drugs with high phenotypic barrier to resistance. Low and high fitness HCVs populations and biological clones derived from them were used to infect hepatoma cells Huh-7.5. Sofosbuvir efficacy was analyzed by measuring virus progeny production ...
Source: Antimicrobial Agents and Chemotherapy - April 10, 2016 Category: Microbiology Authors: Gallego I, Sheldon J, Moreno E, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C Tags: Antimicrob Agents Chemother Source Type: research
Efficacy and safety of telaprevir with pegylated interferon α‐2a and ribavirin in Japanese patients
ConclusionTVR in combination with PEG‐IFNα‐2a/RBV provided a high SVR rate for the treatment of genotype 1 HCV in both treatment‐naïve and relapsed patients in Japan. TVR‐based therapy may provide a useful treatment option for patients who are difficult to treat due to NS5A (Y93, L31) and NS3/4A (D168) variants. (Source: Hepatology Research)
Source: Hepatology Research - April 6, 2016 Category: Internal Medicine Authors: Hiromitsu Kumada, Fumitaka Suzuki, Naohiro Kamiya, Madori Orihashi, Yoshiyuki Nakayasu, Ichimaro Yamada Tags: Original Article Source Type: research
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
CONCLUSIONS: We had success with pegylated interferon-based treatment of AN/AI people with genotypes 2 and 3. However, there were low SVR and high discontinuation rates for those with genotype 1.
PMID: 27029671 [PubMed - in process] (Source: International Journal of Circumpolar Health)
Source: International Journal of Circumpolar Health - April 1, 2016 Category: Global & Universal Tags: Int J Circumpolar Health Source Type: research
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
CONCLUSION: Daclatasvir plus pegIFN/RBV demonstrated noninferiority to telaprevir plus pegIFN/RBV for SVR12 and was well-tolerated in treatment-naive GT1b-infected patients, supporting the use of daclatasvir with other direct-acting antivirals.
PMID: 27022224 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 27, 2016 Category: Gastroenterology Authors: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin P Tags: World J Gastroenterol Source Type: research
Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living‐donor liver transplantation: A Japanese multicenter experience
ConclusionSimeprevir‐based triple therapy for recurrent hepatitis C after living‐donor liver transplantation resulted in a high SVR rate and good tolerability, especially in treatment‐naïve patients. (Source: Hepatology Research)
Source: Hepatology Research - March 26, 2016 Category: Internal Medicine Authors: Yoshihide Ueda, Toru Ikegami, Akihiko Soyama, Nobuhisa Akamatsu, Masahiro Shinoda, Kohei Ishiyama, Masaki Honda, Shigeru Marubashi, Hideaki Okajima, Tomoharu Yoshizumi, Susumu Eguchi, Norihiro Kokudo, Yuko Kitagawa, Hideki Ohdan, Yukihiro Inomata, Hiroaki Tags: Original Article Source Type: research
Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients
Conclusions The most predominant HCV genotype was 1b in patients with HIV/HCV coinfection. Naturally occurring mutations resistant to HCV PIs (simeprevir, vaniprevir, boceprevir, telaprevir, asunaprevir and paritaprevir) pre-existed in patients with HIV/HCV genotype 1b coinfection. The effects of baseline PI resistance on treatment outcome should be further analyzed. (Source: Clinics and Research in Hepatology and Gastroenterology)
Source: Clinics and Research in Hepatology and Gastroenterology - March 22, 2016 Category: Gastroenterology Source Type: research
[Corrections] Corrections
Reddy KR, Zeuzem S, Zoulim F, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015; 15: 27–35—The online appendix of this Article has been corrected as of March 21, 2016. (Source: The Lancet Infectious Diseases)
Source: The Lancet Infectious Diseases - March 22, 2016 Category: Infectious Diseases Tags: Corrections Source Type: research
Chemoselective Intermolecular Hydrogen Bonding In Peptides: An Electronic and Topological Study on the H-Bonding Selectivities in Peptidomimetic HCV Protease Inhibitor Telaprevir
Publication date: Available online 21 March 2016 Source:Computational and Theoretical Chemistry Author(s): Gerald J. Tanoury Chemoselectivity in intermolecular hydrogen bonding in polypeptides is demonstrated via a comprehensive study on the H-bonding characteristics of the peptiomimetic hepatitis C protease inhibitor telaprevir (1) using well-established computational tools. Starting with a QTAIM and NBO analysis of the H-bonding selectivities observed in the crystal structure of 1 and its 4-HBA cocrystal, the analysis was extended to model systems of the amino acid residues of 1 (P1res, P3res, and P4res) complexed ...
Source: Computational and Theoretical Chemistry - March 21, 2016 Category: Chemistry Source Type: research
